BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: Millipore Corporation (MIL) Buys Serologicals Corporation (SERO) For $1.4 Billion


4/25/2006 6:46:05 PM

April 25, 2006 -- Millipore will buy fellow lab tools developer Seriologicals for a total of $1.4 billion, including debt; DOV Pharma said its analgesic for back pain failed its Phase III trial; Surfaxin from Discovery Labs has not achieved its stability parameters, delaying approval; according to Cephalon, the FDA will take an additional three months to decide the fate of Sparlon, the potential therapy for ADHD; Amgen agreed to develop compounds that treat eye diseases for Alcon; Abraxis BioScience bought a Puerto Rican manufacturing facility from Pfizer; ViaCell collaborated with Pall, making it possible to collect umbilical cord blood after a Caesarean section; NeoPharm announced additional results for its brain cancer drug; NeoRx extended its Phase II trial of picoplatin for small-cell lung cancer into Eastern Europe; Peregrine Pharma received a $406,000 Department of Defense grant to study its cancer drug; and EntreMed will enter its breast cancer drug in a Phase Ib study as an adjunct to paclitaxel. The Centient Biotech 200™ was 37 points lower at 3758.74, a drop of .98%. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES